Scholar Rock Holding Corporation (SRRK): Price and Financial Metrics
Scholar Rock Holding Corporation (SRRK)
Today's Latest Price: $13.99 USD
1.26 (-8.26%)
Updated Feb 27 5:21pm
Add SRRK to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
SRRK Stock Summary
- Scholar Rock Holding Corp's stock had its IPO on May 24, 2018, making it an older stock than only 3.1% of US equities in our set.
- With a year-over-year growth in debt of 797.74%, Scholar Rock Holding Corp's debt growth rate surpasses 96.96% of about US stocks.
- As for revenue growth, note that SRRK's revenue has grown 315.94% over the past 12 months; that beats the revenue growth of 97.73% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Scholar Rock Holding Corp are DRNA, BLCM, ADXS, MEIP, and NOVN.
- Visit SRRK's SEC page to see the company's official filings. To visit the company's web site, go to www.scholarrock.com.
SRRK Daily Price Range
SRRK 52-Week Price Range
SRRK Stock Price Chart More Charts
SRRK Price/Volume Stats
| Current price | $13.99 | 52-week high | $23.35 |
| Prev. close | $15.25 | 52-week low | $6.95 |
| Day low | $13.92 | Volume | 112,100 |
| Day high | $15.46 | Avg. volume | 88,569 |
| 50-day MA | $12.59 | Dividend yield | N/A |
| 200-day MA | $12.36 | Market Cap | 415.20M |
Scholar Rock Holding Corporation (SRRK) Company Bio
Scholar Rock Holding Corporation discovers and develops a class of biologic therapies that selectively target dysregulated growth factors in the disease microenvironment by modulating supracellular activation. The company’s drug discovery programs target growth factors which are present in the microenvironments of significant diseases, including fibrosis, musculoskeletal diseases, immuno-oncology, and autoimmune diseases. Its lead products include SRK-015, a selective and local inhibitor of latent myostatin activation for the treatment of primary myopathies. The company was founded in 2012 and is based in Cambridge, Massachusetts.
Top Stories View All
CGC SNDL IIPR GWPH TLRY Cannabis Stocks: The Week in Review
Best & Worst Performing Stock Industries for February 27, 2020
Best & Worst Performing Small Cap Stocks for February 27, 2020
Best & Worst Performing Mid Cap Stocks for February 27, 2020
Best & Worst Performing Large Cap Stocks for February 27, 2020
View All Top Stories
Loading social stream, please wait...